Latest Earnings Results: Q3 '26
Estimated EPS
-$0.24
Reported EPS
-$0.10
Surprise
+57.63%
Estimated Rev
$0.24M
Reported Rev
$0.56M
Surprise
+128.84%
Insight Molecular Diagnostics continues to target outgoing free cash flow of approximately $8M in Q4 2026; Q3 2026 free cash flow was approximately $7.3M, versus prior expectation of $8M.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.20 | -- | -- | N/A |
Q3 '26 | -$0.24 | -$0.10 | 57.63% | BEAT |
Q2 '26 | -$0.24 | -$0.31 | -29.17% | MISSED |
Q1 '26 | -$0.26 | -$0.12 | 54.12% | BEAT |
Q4 '25 | -$0.24 | -$0.72 | -203.16% | MISSED |